MorphoSys AG

June 04, 2013 10:12 ET

Annual General Meeting of MorphoSys AG Approves All Management Proposals

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwired - Jun 4, 2013) - MorphoSys AG / Annual General Meeting of MorphoSys AG Approves All Management Proposals . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at the Company's Annual Shareholder Meeting on Tuesday, 4 June 2013, its shareholders approved the following management proposals put to vote at the meeting:

* Granting full discharge of the members of the Management and Supervisory Boards in respect of their activities during the business year 2012.

* The appointment of PricewaterhouseCoopers AG as auditors of the Company and the MorphoSys Group for the business year 2013.

* The use of the net earnings of MorphoSys AG, Management and Supervisory Boards recommended that the net profit of the business year 2012 is carried forward as accumulated income

* Amendment of the authorization to issue convertible bonds based on the resolution of the Annual General Meeting on May 14, 2008 and the corresponding provision of the Articles of Association to avoid shares with a deviating entitlement to dividend

* The creation of a new Authorized Capital 2013-I with the possibility to exclude pre-emptive rights of the shareholders

"In 2012 we have seen a fundamental re-rating of the company, which was clearly linked to the potential value of our pipeline, not our immediate financial performance. This validates our strategy of investing in proprietary drug programs to create substantial value for our shareholders" commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

At the Annual General Meeting 2013 of MorphoSys AG, 41.6 % of the voting shares were represented.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF):

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Associate Director Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Alexandra Goller
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact